Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Retained Earnings (2016 - 2025)

ImmunityBio (IBRX) has disclosed Retained Earnings for 13 consecutive years, with $29.0 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 100.86% to $29.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.0 million through Dec 2025, up 100.86% year-over-year, with the annual reading at $29.0 million for FY2025, 100.86% up from the prior year.
  • Retained Earnings for Q4 2025 was $29.0 million at ImmunityBio, up from -$3.7 billion in the prior quarter.
  • The five-year high for Retained Earnings was $29.0 million in Q4 2025, with the low at -$3.7 billion in Q3 2025.
  • Average Retained Earnings over 5 years is -$2.0 billion, with a median of -$2.3 billion recorded in 2022.
  • The sharpest move saw Retained Earnings tumbled 59462300.0% in 2022, then soared 100.86% in 2025.
  • Over 5 years, Retained Earnings stood at $4000.0 in 2021, then crashed by 59462300.0% to -$2.4 billion in 2022, then surged by 100.0% to $10000.0 in 2023, then tumbled by 33752580.0% to -$3.4 billion in 2024, then skyrocketed by 100.86% to $29.0 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $29.0 million, -$3.7 billion, and -$3.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.